Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease
Background: Recent research suggests that a significant number of those who receive advanced treatments for Parkinson's disease (PD) do not report improvements for some symptoms, which may relate to their pre-treatment expectations. It is important that expectations of treatment are measured an...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
2021
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/88168 |
| _version_ | 1848764974817607680 |
|---|---|
| author | Loftus, Andrea Nielsen, Chloe Corti, Emily Starkstein, S. Gasson, Natalie Egan, Sarah |
| author_facet | Loftus, Andrea Nielsen, Chloe Corti, Emily Starkstein, S. Gasson, Natalie Egan, Sarah |
| author_sort | Loftus, Andrea |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Background: Recent research suggests that a significant number of those who receive advanced treatments for Parkinson's disease (PD) do not report improvements for some symptoms, which may relate to their pre-treatment expectations. It is important that expectations of treatment are measured and discussed prior to advanced treatment.
Objective: The primary aim of this study was to develop a measure of treatment expectations of two advanced-stage treatments in PD, deep brain stimulation (DBS), and Levodopa/Carbidopa Intestinal Gel (LCIG). A secondary aim was to explore potential predictors of treatment expectations.
Methods: The questionnaire-based measure was developed by researchers in conjunction with a highly experienced clinician, and evaluated treatment expectations in 189 people aged 46-91 years (M = 71.35, SD = 8.73; 61% male) with idiopathic PD.
Results: The overall measure demonstrated excellent internal consistency (α= 0.96). Exploratory factor analysis suggested the scale was unidimensional for both DBS and LCIG. Participant expectations of the two treatments differed significantly, with expectations being higher for DBS. Perceived symptom severity was the strongest predictor of treatment expectations.
Conclusion: This scale has potential to inform clinicians about client expectations prior to advanced stage therapy for PD, with a view to the management of these expectations. Further evaluation of the scale is required across different treatment contexts. |
| first_indexed | 2025-11-14T11:27:53Z |
| format | Journal Article |
| id | curtin-20.500.11937-88168 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| language | eng |
| last_indexed | 2025-11-14T11:27:53Z |
| publishDate | 2021 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-881682022-03-31T04:27:40Z Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease Loftus, Andrea Nielsen, Chloe Corti, Emily Starkstein, S. Gasson, Natalie Egan, Sarah Levodopa/carbidopa intestinal gel Parkinson’s disease deep brain stimulation psychological quality of life treatment expectations Aged Aged, 80 and over Antiparkinson Agents Carbidopa Drug Combinations Female Gels Humans Levodopa Male Middle Aged Motivation Parkinson Disease Prognosis Treatment Outcome Background: Recent research suggests that a significant number of those who receive advanced treatments for Parkinson's disease (PD) do not report improvements for some symptoms, which may relate to their pre-treatment expectations. It is important that expectations of treatment are measured and discussed prior to advanced treatment. Objective: The primary aim of this study was to develop a measure of treatment expectations of two advanced-stage treatments in PD, deep brain stimulation (DBS), and Levodopa/Carbidopa Intestinal Gel (LCIG). A secondary aim was to explore potential predictors of treatment expectations. Methods: The questionnaire-based measure was developed by researchers in conjunction with a highly experienced clinician, and evaluated treatment expectations in 189 people aged 46-91 years (M = 71.35, SD = 8.73; 61% male) with idiopathic PD. Results: The overall measure demonstrated excellent internal consistency (α= 0.96). Exploratory factor analysis suggested the scale was unidimensional for both DBS and LCIG. Participant expectations of the two treatments differed significantly, with expectations being higher for DBS. Perceived symptom severity was the strongest predictor of treatment expectations. Conclusion: This scale has potential to inform clinicians about client expectations prior to advanced stage therapy for PD, with a view to the management of these expectations. Further evaluation of the scale is required across different treatment contexts. 2021 Journal Article http://hdl.handle.net/20.500.11937/88168 10.3233/jpd-212777 eng restricted |
| spellingShingle | Levodopa/carbidopa intestinal gel Parkinson’s disease deep brain stimulation psychological quality of life treatment expectations Aged Aged, 80 and over Antiparkinson Agents Carbidopa Drug Combinations Female Gels Humans Levodopa Male Middle Aged Motivation Parkinson Disease Prognosis Treatment Outcome Loftus, Andrea Nielsen, Chloe Corti, Emily Starkstein, S. Gasson, Natalie Egan, Sarah Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease |
| title | Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease |
| title_full | Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease |
| title_fullStr | Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease |
| title_full_unstemmed | Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease |
| title_short | Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease |
| title_sort | measuring general expectations of advanced stage treatment outcomes in parkinson's disease |
| topic | Levodopa/carbidopa intestinal gel Parkinson’s disease deep brain stimulation psychological quality of life treatment expectations Aged Aged, 80 and over Antiparkinson Agents Carbidopa Drug Combinations Female Gels Humans Levodopa Male Middle Aged Motivation Parkinson Disease Prognosis Treatment Outcome |
| url | http://hdl.handle.net/20.500.11937/88168 |